Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Tislelizumab and Capecitabine in High-Risk Intrahepatic Cholangiocarcinoma
NCT04782804Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04782804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782804.